Baird Highlighgs NewLink Genetics' (NLNK) IDO Program Amid Algenpantucel-L Failure
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Mizuho Securities Cuts Price Target on NewLink Genetics (NLNK) Following Failed IMPRESS Trial
May 10, 2016 1:22 PM EDTMizuho Securities maintained a Buy rating on NewLink Genetics (NASDAQ: NLNK), and cut the price target to $20.00 (from $52.00), following a failed IMPRESS Phase III trial.
Analyst Eric Criscuolo commented, "We reiterate our Buy rating but lower our PT from $52 to $20... More
NewLink Genetics (NLNK) Phase 3 Study of Algenpantucel-L Did Not Achieve Primary Endpoint
May 9, 2016 4:03 PM EDTNewLink Genetics Corporation (NASDAQ: NLNK) announced today results of its Phase 3 clinical trial for algenpantucel-L for patients with resected pancreatic cancer.
The IMPRESS Phase 3 study of algenpantucel-L for patients with resected pancreatic cancer did not achieve its primary endpoint. Overall survival from time of randomization was 29.3 months for both groups combined. There was no statistically significant difference between the two groups. The... More
